WO1996027384A3 - Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase - Google Patents

Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase Download PDF

Info

Publication number
WO1996027384A3
WO1996027384A3 PCT/IB1996/000176 IB9600176W WO9627384A3 WO 1996027384 A3 WO1996027384 A3 WO 1996027384A3 IB 9600176 W IB9600176 W IB 9600176W WO 9627384 A3 WO9627384 A3 WO 9627384A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
iso
inhibitor
phosphodiesterase
Prior art date
Application number
PCT/IB1996/000176
Other languages
French (fr)
Other versions
WO1996027384A2 (en
Inventor
Georges Cehovic
Patrice Andre
Original Assignee
Dior Christian Parfums
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dior Christian Parfums filed Critical Dior Christian Parfums
Priority to EP96903160A priority Critical patent/EP0813418A2/en
Priority to JP8526738A priority patent/JPH11501311A/en
Publication of WO1996027384A2 publication Critical patent/WO1996027384A2/en
Publication of WO1996027384A3 publication Critical patent/WO1996027384A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Abstract

The present invention relates to a composition for improving skin conditions containing as active ingredient a specific inhibitor of human skin iso PDE and a dermatological acceptable carrier. It also relates to a method for improving skin conditions comprising the application of this composition.
PCT/IB1996/000176 1995-03-08 1996-03-06 Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase WO1996027384A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96903160A EP0813418A2 (en) 1995-03-08 1996-03-06 Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase
JP8526738A JPH11501311A (en) 1995-03-08 1996-03-06 Compositions for treating skin diseases comprising an inhibitor of cutaneous isophosphodiesterase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40113595A 1995-03-08 1995-03-08
US08/401,135 1995-03-08

Publications (2)

Publication Number Publication Date
WO1996027384A2 WO1996027384A2 (en) 1996-09-12
WO1996027384A3 true WO1996027384A3 (en) 1996-10-31

Family

ID=23586449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000176 WO1996027384A2 (en) 1995-03-08 1996-03-06 Composition for treating skin conditions comprising an inhibitor of skin iso-phosphodiesterase

Country Status (3)

Country Link
EP (1) EP0813418A2 (en)
JP (1) JPH11501311A (en)
WO (1) WO1996027384A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774905B1 (en) * 1998-02-17 2000-06-09 Codif International Sa USE OF A COSMETIC COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WHICH INCLUDES A PYRONE GROUPING
FR2885301B1 (en) * 2005-03-17 2011-03-04 Jean Noel Thorel COSMETIC OR DERMATOLOGICAL COMPOSITION FOR DECREASING AND / OR CORRECTING THE REDNESS OF THE SKIN
JP5550839B2 (en) * 2009-02-09 2014-07-16 株式会社 資生堂 Whitening agent

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978213A (en) * 1972-07-10 1976-08-31 Nelson Research & Development Company Cosmetic use of cyclic amp and phosphodiesterase inhibitors
US4146621A (en) * 1973-01-16 1979-03-27 The Regents Of The University Of Michigan Process of treating proliferative skin diseases
JPS59148712A (en) * 1983-02-15 1984-08-25 Kingo Yoshida Cosmetic and drug containing tannin
EP0275005A2 (en) * 1987-01-14 1988-07-20 INDENA S.p.A. Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
DE3840832A1 (en) * 1988-12-03 1990-06-07 Mueller Robert Dr Product for external use
JPH037234A (en) * 1989-03-15 1991-01-14 Nippon Oil & Fats Co Ltd Physiological substance, production thereof and medicine, cosmetic and physiologically functional food containing the same substance
EP0427026A2 (en) * 1989-10-27 1991-05-15 INDENA S.p.A. Compositions for treating fat deposits in humans
JPH0429934A (en) * 1990-05-28 1992-01-31 Seiichi Umeda Externally applicable composition containing extracted essence of ginkgo leaf
JPH0449226A (en) * 1990-06-15 1992-02-18 Masaichi Sakurashita Green tea bath medicine
JPH04321616A (en) * 1991-04-19 1992-11-11 Kose Corp Skin medicine for external use
JPH0532556A (en) * 1991-07-30 1993-02-09 Kose Corp Skin agent for external use
WO1994020066A1 (en) * 1993-03-01 1994-09-15 Unilever Plc Sunscreen composition
WO1995000139A1 (en) * 1993-06-18 1995-01-05 Smithkline Beecham Corporation Compounds
JPH0711230A (en) * 1993-06-25 1995-01-13 Maruzen Pharmaceut Co Ltd Ultraviolet absorber

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978213A (en) * 1972-07-10 1976-08-31 Nelson Research & Development Company Cosmetic use of cyclic amp and phosphodiesterase inhibitors
US4146621A (en) * 1973-01-16 1979-03-27 The Regents Of The University Of Michigan Process of treating proliferative skin diseases
JPS59148712A (en) * 1983-02-15 1984-08-25 Kingo Yoshida Cosmetic and drug containing tannin
EP0275005A2 (en) * 1987-01-14 1988-07-20 INDENA S.p.A. Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
DE3840832A1 (en) * 1988-12-03 1990-06-07 Mueller Robert Dr Product for external use
JPH037234A (en) * 1989-03-15 1991-01-14 Nippon Oil & Fats Co Ltd Physiological substance, production thereof and medicine, cosmetic and physiologically functional food containing the same substance
EP0427026A2 (en) * 1989-10-27 1991-05-15 INDENA S.p.A. Compositions for treating fat deposits in humans
JPH0429934A (en) * 1990-05-28 1992-01-31 Seiichi Umeda Externally applicable composition containing extracted essence of ginkgo leaf
JPH0449226A (en) * 1990-06-15 1992-02-18 Masaichi Sakurashita Green tea bath medicine
JPH04321616A (en) * 1991-04-19 1992-11-11 Kose Corp Skin medicine for external use
JPH0532556A (en) * 1991-07-30 1993-02-09 Kose Corp Skin agent for external use
WO1994020066A1 (en) * 1993-03-01 1994-09-15 Unilever Plc Sunscreen composition
WO1995000139A1 (en) * 1993-06-18 1995-01-05 Smithkline Beecham Corporation Compounds
JPH0711230A (en) * 1993-06-25 1995-01-13 Maruzen Pharmaceut Co Ltd Ultraviolet absorber

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Ginkor gel", CD-ROM VIDAL 1992, XP002012149 *
A. BERETZ: "Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate", BIOCHEM. PHARMACOL., vol. 35, no. 2, 1986, pages 257 - 262, XP000576368 *
C.D. NICHOLSON: "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", TRENDS PHARMACOL. SCI., vol. 12, no. 1, 1991, pages 19 - 27, XP002012152 *
H. IIZUKA: "Cyclic nucleotide-phosphodiesterase in the uninvolved and involved skin of psoriasis", J. INVEST. DERMATOL., vol. 70, no. 5, 1978, pages 246 - 249, XP000576377 *
HOLLA S W J ET AL: "ADENOSINE 3': 5'-CYCLIC MONOPHOSPHATE PHOSPHODIESTERASE IN SKIN II. LEVELS IN ATOPIC DERMATITIS", BRITISH JOURNAL OF DERMATOLOGY, vol. 86, no. 2, 1 February 1972 (1972-02-01), pages 147 - 149, XP000576543 *
J. A. BEAVO: "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", TRENDS PHARMACOL. SCI., vol. 11, no. 4, 1990, pages 150 - 155, XP002012151 *
J.E. BIRNBAUM: "Cyclic AAMP phosphodiesterase and epidermal mitosis", J. INVEST. DERMATOL., vol. 67, no. 2, 1976, pages 235 - 239, XP002012150 *
L.J. RUSIN: "Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro", J. INVEST. DERMATOL., vol. 71, no. 2, 1978, pages 154 - 156, XP000577437 *
MAHRLE G ET AL: "LOCALIZATION AND ACTIVITY OF TISSUE BOUND CYCLIC NUCLEOTIDE PHOSPHODIESTERASE IN NORMAL AND LACK OF CHANGES IN PSORIATIC HUMAN SKIN", BRITISH JOURNAL OF DERMATOLOGY, vol. 95, no. 6, 1 December 1976 (1976-12-01), pages 591 - 598, XP000576549 *
O. NEMOTO: "Cyclic AMP-dependent protein kinase isozymes of pig skin and human skin from normal and psoriatic subjects", J. INVEST. DERMATOL., vol. 80, no. 2, 1983, pages 111 - 115, XP000576373 *
PATENT ABSTRACTS OF JAPAN vol. 008, no. 279 (C - 257) 20 December 1984 (1984-12-20) *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 123 (C - 0816) 26 March 1991 (1991-03-26) *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 194 (C - 0938) 11 May 1992 (1992-05-11) *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 234 (C - 0945) 29 May 1992 (1992-05-29) *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 158 (C - 1041) 29 March 1993 (1993-03-29) *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 327 (C - 1073) 22 June 1993 (1993-06-22) *
PATENT ABSTRACTS OF JAPAN vol. 95, no. 001 *
S. WRIGHT: "Cyclic adenosine monophosphate-phosphodiesterase activity in cultured keratinocytes from patients with atopic eczema", J. DERMATOL. SCI., vol. 2, no. 4, 1991, pages 263 - 267, XP000578447 *
W. KRAUSE: "Anti-inflammatory activity of rolipram in a rat edema model", ARZNEIMITTEL-FORSCHUNG, vol. 44, no. 2, 1994, pages 163 - 165, XP000590808 *
W.J. PLEDGER: "Separation of multiple forms of cyclic nucleotide phosphodiesterases from rat brain by electrofocusing", BIOCHIM. BIOPHYS. ACTA, vol. 370, no. 1, 1974, pages 242 - 248, XP000578445 *
W.J. THOMSON: "Multiple cyclic nucleotide phosphodiesterase activities from rat brain", BIOCHEMISTRY, vol. 10, no. 2, 1971, pages 311 - 316, XP002012380 *

Also Published As

Publication number Publication date
JPH11501311A (en) 1999-02-02
WO1996027384A2 (en) 1996-09-12
EP0813418A2 (en) 1997-12-29

Similar Documents

Publication Publication Date Title
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
AU4883096A (en) Nitric oxide synthase inhibitors
AU8089494A (en) Composition and method for treating blood vessel disorders of the skin using vitamin
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
MXPA01009415A (en) Ascorbic acid composition and method for treatment of aging or damaged skin.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
EP0728471A3 (en) Cosmetic compositions for reducing or preventing signs of cellulite
EP0868916A3 (en) Reduction inhibitory agent for active-oxygen eliminating activity
ZA948778B (en) Cosmetic method for treatment of skin
AU2462697A (en) Skin tightening formulation and method of treating skin
EP0679393A3 (en) Pharmaceutical composition for treating osteoporosis containing xanthohumol
MX9710252A (en) Use of one or more peptides in a cosmetic composition or for the preparation of a medicament.
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
AU3082699A (en) Method of treating skin irritation
UA35611C2 (en) Topical composition for inhibiting hair growth in mammals, method for application and topical composition for delivering water-soluble pharmaceutical to skin
AU2836499A (en) Cosmetic method of treating skin
NZ506681A (en) Disinfecting composition
WO1998018440A3 (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skin
AU2002220679A1 (en) Cosmetic method of treating skin
AU1378197A (en) Compositions containing vitamin d derivatives for treatment of photodamaged skin
ZA948781B (en) Cosmetic method for treatment of skin
CA2318932A1 (en) Deodorant composition containing d-amino acid
EP0744176A3 (en) Methods for inhibiting bone loss
CA2282682A1 (en) Tazarotene and corticosteroid treatment for psoriasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 526738

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996903160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996903160

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996903160

Country of ref document: EP